Vitiligo under anti–programmed cell death-1 therapy is associated with increased survival in melanoma patients - 17/01/20

Charlée Nardin, MD ^{a, b, ⁎} , Anne Jeand'heur, MD ^a, Kévin Bouiller, MD ^c, Marie Blanche Valnet-Rabier, MD ^d, Flora Dresco, MD ^a, Julie Castagna, MD ^a, Adrien Mareschal, MD ^a, Clémentine Carlet, MD ^a, Virginie Nerich, MD ^{b, e}, Samuel Limat, MD, PhD ^{b, e}, Eve Puzenat, MD ^a, François Aubin, MD, PhD ^{a, ⁎}

^a Department of Dermatology and Inserm UMR1098, University Hospital, Besançon, France 

^b Inserm UMR1098, Université Bourgogne Franche-Comté, Besançon, France 

^c Department of Infectious Diseases, University Hospital, Besançon, France 

^d Department of Pharmacovigilance, University Hospital, Besançon, France 

^e Department of Pharmacy, University Hospital, Besançon, France 

^∗Reprint requests: Charlée Nardin, Department of Dermatology, University Hospital of Besançon, 3 Blvd Alexandre Fleming, 25030 Besançon, FranceDepartment of DermatologyUniversity Hospital of Besançon3 Blvd Alexandre FlemingBesançon25030France^∗Correspondence to: François Aubin, MD, PhD, Department of Dermatology, University Hospital of Besançon, 3 Boulevard Alexandre Fleming, 25030 Besançon, FranceDepartment of DermatologyUniversity Hospital of Besançon3 Boulevard Alexandre FlemingBesançon25030France